Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual Gen...
PRESS RELEASE: BIGBEN announces the temporary suspension of trading in its shares on Euronext Paris and its bonds on Euronext Access Paris Press Release Lesquin, 20 February 2026, 7:30 BIGBEN announces the temporary suspension of trading in its shares on Euronext Paris and its bonds on Euronext Access Paris Lesquin, 20 February 2026, Bigben Interactive (the “Company”) announces that it has requested Euronext Paris to temporarily suspend trading in its shares on the Euronext Paris regulat...
COMMUNIQUE DE PRESSE: BIGBEN annonce la suspension temporaire du cours de ses actions sur Euronext Paris et de ses obligations sur Euronext Access Paris Communiqué de presseLesquin, 20 février 2026, 7H30 BIGBEN annonce la suspension temporaire du cours de ses actions sur Euronext Paris et de ses obligations sur Euronext Access Paris Lesquin, le 20 février 2026, Bigben Interactive (la « Société ») annonce avoir demandé à Euronext Paris la suspension temporaire du cours de ses actions sur le marché réglementé Euronext Paris (ISIN : FR0000074072) et de ses obligations échangeables en actions...
PRESS RELEASE: NACON announces the temporary suspension of trading in its shares on Euronext Paris Press Release Lesquin, 20 February 2026, 7.30 NACON announces the temporary suspension of trading in its shares on Euronext Paris Lesquin, 20 February 2026, Nacon (the “Company”) announces that it has requested Euronext Paris to temporarily suspend trading in its shares on the Euronext Paris regulated (ISIN : FR0013482791) as of market opening today. On 17 February 2026, the Company acknowledges the press release issued on the same ...
COMMUNIQUE DE PRESSE: NACON annonce la suspension temporaire du cours de ses actions sur Euronext Paris Communiqué de presse Lesquin, 20 février 2026, à 7H30 NACON annonce la suspension temporaire du cours de ses actions sur Euronext Paris Lesquin, le 20 février 2026, Nacon (la « Société ») annonce avoir demandé à Euronext Paris la suspension temporaire du cours de ses actions sur le marché réglementé Euronext Paris (ISIN : FR0013482791) à compter de l’ouverture des marchés ce jour. Le 17 février 2026, la Société annonçait avoir pris acte ...
PRESS RELEASE: NACON acknowledges the press release issued today by its majority shareholder, Bigben Interactive, and announces that it is carefully assessing the consequences for its own activities. Press Release Lesquin, 17 February 2026, 20.30 pm Nacon (the ‘Company’) acknowledges the press release issued today by its majority shareholder, Bigben Interactive, and announces that it is carefully assessing the consequences for its own activities. The Company acknowledges the press release issued today by its majority shareholder, ...
COMMUNIQUE DE PRESSE: Nacon prend acte du communiqué de presse publié ce jour par son actionnaire majoritaire, la société Bigben Interactive, et annonce en évaluer attentivement les conséquences sur ses propres activités. Communiqué de presse Lesquin, 17 février 2026, à 20h30 Nacon (la « Société ») prend acte du communiqué de presse publié ce jour par son actionnaire majoritaire, la société Bigben Interactive, et annonce en évaluer attentivement les conséquences sur ses propres activités. La Société prend acte du communiqué de pr...
PRESS RELEASE: BIGBEN ANNOUNCES IMPORTANT INFORMATION REGARDING THE PARTIAL REPAYMENT OF ITS BOND LOAN Press ReleaseLesquin, 17 February 2026, 20.30 pm BIGBEN ANNOUNCES IMPORTANT INFORMATION REGARDING THE PARTIAL REPAYMENT OF ITS BOND LOAN Bigben Interactive (the ‘Company’) announces that, due to the unexpected and late refusal of its banking pool to respond to the drawdown notice sent to it in connection with the Partial Refinancing of the Bonds, the Company is currently unable to proceed with the Partial Redemption of the Outstanding Bonds as originally planned.In light of this situatio...
COMMUNIQUE DE PRESSE: BIGBEN annonce une information importante relative au remboursement partiel de son emprunt obligataire Communiqué de presseLesquin, 17 février 2026, 20h30 BIGBEN annonce une information importante relative au remboursement partiel de son emprunt obligataire Bigben Interactive (la « Société ») annonce qu'en raison du refus inattendu et tardif de son pool bancaire de donner suite à l’avis de tirage qui lui a été adressé dans le cadre du Refinancement Partiel des Obligations, la Société se trouve, à date, dans l'impossibilité de procéder au Remboursement Partiel de l'En...
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.